LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (Keros or the Firm) (Nasdaq: KROS), a clinical-stage biopharmaceutical firm centered on creating and commercializing novel therapeutics to deal with a variety of sufferers with problems which are linked to dysfunctional signaling of the reworking progress factor-beta (TGF-ß) household of proteins, at present introduced that Keros’ Chair and Chief Government Officer Jasbir S. Seehra, Ph.D., will current on the following healthcare conferences:
Piper Sandler 36th Annual Healthcare Convention
- Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Jap time
- Hyperlink: https://occasion.webcasts.com/starthere.jsp?ei=1699705&tp_key=2752037800
- Format: Fireplace Chat Presentation
7th Annual Evercore HealthCONx Convention
- Date and Time: Wednesday, December 4, 2024 at 3:00 p.m. Jap time
- Hyperlink: https://wsw.com/webcast/evercore44/kros/2395197
- Format: Fireplace Chat Presentation
For every presentation, an archived replay will likely be accessible within the Buyers part of the Keros web site at https://ir.kerostx.com for as much as 90 days following the conclusion of every occasion.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical firm centered on creating and commercializing novel therapeutics to deal with a variety of sufferers with problems which are linked to dysfunctional signaling of the TGF-ß household of proteins. The Firm is a frontrunner in understanding the function of the TGF-ß household of proteins, that are grasp regulators of the expansion, restore and upkeep of plenty of tissues, together with blood, bone, skeletal muscle, adipose and coronary heart tissue. By leveraging this understanding, Keros has found and is creating protein therapeutics which have the potential to supply significant and doubtlessly disease-modifying profit to sufferers. Keros’ lead product candidate, elritercept (KER-050), is being developed for the therapy of low blood cell counts, or cytopenias, together with anemia and thrombocytopenia, in sufferers with myelodysplastic syndromes and in sufferers with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the therapy of pulmonary arterial hypertension for the therapy of cardiovascular problems. Keros’ third product candidate, KER-065, is being developed for the therapy of weight problems and for the therapy of neuromuscular ailments.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Supply: Keros Therapeutics, Inc.
